1. Perlu dilakukan uji stabilitas sediaan, uji iritasi pada mukosa dari sediaan microsponge gel vagina dari ITZ
2. Perlu dilakukan uji aktivitas antifungi dalam formulasi *microsponge* ITZ pada sediaan gel vagina.
3. Perlu dilakukan penentuan profil kinetika secara *in-vivo* pada hewan coba yang sesuai dari sediaan *microsponge* gel vagina dari ITZ

DAFTAR PUSTAKA

Abdullahi Nasir, I., Uchenna, E., Onyia, J., Ifunanya, A.L., 2015. Prevalence of vulvovaginal candidiasis among nonpregnant women attending a tertiary health care facility in Abuja, Nigeria. Res. Rep. Trop. Med. 37.

Andrade, A.O., Parente, M.E., Ares, G., 2014. Screening of mucoadhesive vaginal gel formulations. Brazilian J. Pharm. Sci. 50, 931–942.

Arfiputri, D.S., Hidayati, A.N., Handayani, S., Ervianti, E., 2018. Risk factors of vulvovaginal candidiasis in dermatovenereology outpatients clinic of soetomo general hospital, Surabaya, Indonesia. African J. Infect. Dis. 12, 90–94.

Asati, S., Jain, S., Choubey, A., 2019. Bioadhesive or Mucoadhesive Drug Delivery System: A Potential Alternative to Conventional Therapy. J. Drug Deliv. Ther. 9, 858–867.

Aslani, A., Ghannadi, A., Najafi, H., 2013. Design, formulation and evaluation of a mucoadhesive gel from Quercus brantii L. and coriandrum sativum L. as periodontal drug delivery. Adv. Biomed. Res. 2, 21.

Berginc, K., Nata, Š., Basnet, P., Kristl, A., 2012. Development and Evaluation of an In Vitro Vaginal Model for Assessment of Drug ' s Biopharmaceutical Properties : Curcumin. Am. Assoc. Pharm. Sci. 13, 1045–1053.

Berretta, A.A., Castro, P.A. De, Cavalheiro, A.H., Fortes, V.S., Bom, V.P., Nascimento, A.P., Marquele-oliveira, F., Pedrazzi, V., Naira, L., Ramalho, Z., Goldman, G.H., 2013. Evaluation of Mucoadhesive Gels with Propolis (EPP-AF) in Preclinical Treatment of Candidiasis Vulvovaginal Infection. Hindawi Publ. Corp. Evidence-Based Complement. Altern. Med. 2013, 1–18.

Bitew, A., Abebaw, Y., 2018. Vulvovaginal candidiasis: Species distribution of Candida and their antifungal susceptibility pattern. BMC Womens. Health 18, 1–10.

Blanco-Fuente, H., Esteban-Fernández, B., Blanco-Méndez, J., Otero-Espinar, F.J., 2002. Use of β-cyclodextrins to prevent modifications of the properties of carbopol hydrogels due to carbopol-drug interactions. Chem. Pharm. Bull. 50, 40–46.

BPOM RI, 2017. Itraconazol. Badan Pengawas. Obat dan Makanan.

Cassone, A., 2015. Vulvovaginal Candida albicans infections: Pathogenesis, immunity and vaccine prospects. BJOG An Int. J. Obstet. Gynaecol. 122, 785–794.

Chaliha, C., Khullar, V., 2006. Management of vaginal prolapse. Women's Heal. 2, 279–287.

Chatterjee, B., Amalina, N., Sengupta, P., Mandal, U.K., 2017. Mucoadhesive polymers and their mode of action: A recent update. J. Appl. Pharm. Sci. 7, 195–203.

Chen, Y., Bruning, E., Rubino, J., Eder, S.E., 2017. Role of female intimate hygiene in vulvovaginal health: Global hygiene practices and product usage. Women's Heal. 13, 58–67.

Chudasama, A., Shah, B., Patel, V., Nivsarkar, M., Vasu, K., Shishoo, C., 2015. Development of self emulsifying drug delivery system of itraconazole for oral delivery: formulation and pharmacokinetic consideration. J. Pharm. Investig. 45, 271–283.

Da Silva, J.B., Khutoryanskiy, V. V., Bruschi, M.L., Cook, M.T., 2017. A mucosa-mimetic material for the mucoadhesion testing of thermogelling semi-solids. Int. J. Pharm. 528, 586–594.

De Araújo Pereira, R.R., Bruschi, M.L., 2012. Vaginal mucoadhesive drug delivery systems. Drug Dev. Ind. Pharm. 38, 643–652.

Dineshmohan, S., Gupta, V.R.M., 2017. Formulation of fluconazole as topical antifungal gels by microsponge based delivery systems. Indones. J. Pharm. 28, 158–167.

Faria, M.J., Machado, R., Ribeiro, A., Gonçalves, H., Real Oliveira, M.E.C.D., Viseu, T., Neves, J. Das, Lúcio, M., 2019. Rational development of liposomal hydrogels: A strategy for topical vaginal antiretroviral drug delivery in the context of HIV prevention. Pharmaceutics 11, 1–27.

Fiume, M.M., Heldreth, B., Bergfeld, W.F., Belsito, D. V., Hill, R.A., Klaassen, C.D., Liebler, D., Marks, J.G., Shank, R.C., Slaga, T.J., Snyder, P.W., Andersen, F.A., 2013. Safety Assessment of Triethanolamine and Triethanolamine-Containing Ingredients as Used in Cosmetics. Int. J. Toxicol. 32, 59S-83S.

Francois, M., Snoeckx, E., Putteman, P., Wouters, F., De Proost, E., Delaet, U., Peeters, J., Brewster, M.E., 2003. A mucoadhesive, cyclodextrin-based vaginal cream formulation of itraconazole. AAPS J. 5, 1–5.

Gaikwad, V.L., D.Yadav, V., Dhavale, R.P., Choudhari, P.B., Jadhav, S.D., 2012. Effect of Carbopol 934 and 940 on Fluconazole Release from Topical Gel Formulation: A Factorial Approach. J. Curr. Pharma Res. 2, 487–493.

Gibson, M., 2016. Pharmaceutical Preformulation and Formulation. Mcgraw-hill, New York.

Gowda, D. V., Khan, M.S., Mohammed, N., Shivakumar, H.G., 2010. Preparation and evaluation of microporous drug delivery system. Int. J. Pharma Bio Sci. 1, 294–301.

Graziottin, A., Gambini, D., 2015. Anatomy and physiology of genital organs - women, 1st ed, Handbook of Clinical Neurology. Elsevier B.V.

Johal, H.S., Garg, T., Rath, G., Goyal, A.K., 2016. Advanced topical drug delivery system for the management of vaginal candidiasis. Drug Deliv. 23, 550–563.

Kapupara, P.P., Dholakia, S.P., Patel, V.P., Suhagia, B.N., 2011. Journal of Chemical and Pharmaceutical Research preparations. J. Chem. Pharm. Res. 3, 287–294.

Karthikeyan, K., Durgadevi, R., Saravanan, K., Shivsankar, K., Usha, S., Saravanan, M., 2012. Formulation of bioadhesive carbomer gel incorporating drug-loaded gelatin microspheres for periodontal therapy. Trop. J. Pharm. Res. 11, 335–343.

Kasar, P.M., Kale, K., Phadtare, D.G., 2018. Formulation and Evaluation of Topical Antifungal Gel Containing Itraconazole. Int. J. Curr. Pharm. Res. 10, 71.

Kim, J.Y., Rhee, Y.S., Park, C.W., Ha, J.M., Park, E.S., 2014. Preparation and evaluation of dual-mode floating gastroretentive tablets containing itraconazole. Drug Deliv. 21, 519–529.

Kumar, M., 2018. Review On Vaginal Drug Delivery System. Indo Am. J. Pharm. Res. 8.

Lestner, J., Hope, W.W., 2013. Itraconazole: An update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. Expert Opin. Drug Metab. Toxicol. 9, 911–926.

Liu, L., Bello, A., Dresser, M.J., Heald, D., Komjathy, S.F., O'Mara, E., Rogge, M., Stoch, S.A., Robertson, S.M., 2016. Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies. J. Clin. Pharmacol. 56, 143–151.

Loyd V. Allen, 2009. Handbook of Pharmaceutical Excipient. Sixth Edition, Sixth. ed. Pharmaceutical Press and American Pharmacists Assosiation, London.

Machado, G.C., Maher, C.G., Ferreira, P.H., Pinheiro, M.B., Lin, C.W.C., Day, R.O., McLachlan, A.J., Ferreira, M.L., 2015. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: Systematic review and meta-analysis of randomised placebo controlled trials. BMJ 350, 1–13.

Mandal, A., Majumdar, A., Malviya, N., 2018. Formulation and evaluation of chitosan microspheres for the topical delivery of itraconazole 12.

Manna, S., Lakshmi, U.S., Racharla, M., Sinha, P., Kanthal, L.K., Kumar, S.P.N., 2016. Bioadhesive HPMC gel containing gelatin nanoparticles for intravaginal delivery of tenofovir. J. Appl. Pharm. Sci. 6, 22–29.

Mirza, M.A., Panda, A.K., Asif, S., Verma, D., Talegaonkar, S., Manzoor, N., Khan, A., Ahmed, F.J., Dudeja, M., Iqbal, Z., 2016. A vaginal drug delivery model. Drug Deliv. 23, 3123–3134.

Notario-Pérez, F., Martín-Illana, A., Cazorla-Luna, R., Ruiz-Caro, R., Tamayo, A., Rubio, J., Veiga, M.D., 2020. Mucoadhesive vaginal discs based on cyclodextrin and surfactants for the controlled release of antiretroviral drugs to prevent the sexual transmission of HIV. Pharmaceutics 12.

Osmani, R.A.M., Aloorkar, N.H., Ingale, D.J., Kulkarni, P.K., Hani, U., Bhosale, R.R., Jayachandra Dev, D., 2015. Microsponges based novel drug delivery system for augmented arthritis therapy. Saudi Pharm. J. 23, 562–572.

Pandit, A.P., Patel, S.A., Bhanushali, V.P., Kulkarni, V.S., Kakad, V.D., 2017. Nebivolol-Loaded Microsponge Gel for Healing of Diabetic Wound. AAPS PharmSciTech 18, 846–854.

Patel, N., Padia, N., Vadgama, N., Raval, M., Sheth, N., 2016. Formulation and evaluation of microsponge gel for topical delivery of fluconazole for fungal therapy. J. Pharm. Investig. 46, 221–238.

Pramanik, J., Ray, S., Kundu, S., Basak, T., Mondal, S., Panigrahi, S., Bala, N.N., Mahata, P.P., 2018. Modern Approaches of Mucoadhesive Drug Delivery. World J. Pharm. Res. 7, 381–403.

Rahmawati, D.A., Setiawan, I., 2019. The Formulation and Physical Stability Test of Gel Fruit Strawberry Extract (Fragaria x ananassa Duch.). J. Nutraceuticals Herb. Med. 2, 38–46.

Raymond C Rowe, P.J.S. and M.E.Q., 2015. Handbook of Pharmaceutical Excipients, 6th ed. Pharmaceutical Pres.

Rençber, S., Karavana, S.Y., Şenyiğit, Z.A., Eraç, B., Limoncu, M.H., Baloğlu, E., 2017. Mucoadhesive in situ gel formulation for vaginal delivery of clotrimazole: formulation, preparation, and in vitro/in vivo evaluation. Pharm. Dev. Technol. 22, 551–561.

Rowe, R.C., Sheskey, P.J., Quinn, M.E., 2009. Excipients.

Roy, A., Choudhury, A., Bahadur, S., Saha, S., 2017. Preparation and Evaluation of Plant Bioactive Vaginal Formulation. Indo Am. J. Pharm. Sci. 3, 1673–1681.

Salah, S., Awad, G.E.A., Makhlouf, A.I.A., 2018. Improved vaginal retention and enhanced antifungal activity of miconazole microsponges gel: Formulation development and in vivo therapeutic efficacy in rats. Eur. J. Pharm. Sci. 114, 255–266.

Sangeetha, S.S., Karki, R., 2015. Formulation and evaluation of liposomes in carbopol gels for mixed vaginal infections. Der Pharm. Lett. 7, 291–299.

Sanz, R., Clares, B., Mallandrich, M., Suñer-Carbó, J., Montes, M.J., Calpena, A.C., 2018a. Development of a mucoadhesive delivery system for control release of doxepin with application in vaginal pain relief associated with gynecological surgery. Int. J. Pharm. 535, 393–401.

Sanz, R., Clares, B., Mallandrich, M., Suñer-Carbó, J., Montes, M.J., Calpena, A.C., 2018b. Development of a mucoadhesive delivery system for control release of doxepin with application in vaginal pain relief associated with

gynecological surgery. Int. J. Pharm. 535, 393–401.

Sayuti, N.A., 2015. Formulasi dan Uji Stabilitas Fisik Sediaan Gel Ekstrak Daun Ketepeng Cina (Cassia alata L.). J. Kefarmasian Indones. 5, 74–82.

Semwal, R.B.R., 2018. Mucoadhesive assessment – An encyclopedic review Mucoadhesive assessment – An encyclopedic review. Curr. Med. Drug Res. 2.

Shankar, N.B., Kumar, R.P., Kumar, N.U., Brata, B.B., 2010. Development and characterization of bioadhesive gel of microencapsulated metronidazole for vaginal use. Iran. J. Pharm. Res. 9, 209–219.

Sharma, S., Sharma, A., Kaur, C., 2020. MICROSPONGES: AS A TOPICAL DRUG DELIVERY SYSTEM. Dep. Pharm. Pharm. Res. Div. 11, 524–534.

Singh, C., Jain, K., Kumar, C., Agarwal, K., 2009. Design and in vitro evaluation of mucoadhesive microcapsules of pioglitazone . J. Young Pharm. 1, 195.

Srikrishna, S., Cardozo, L., 2013. The vagina as a route for drug delivery: A review. Int. Urogynecol. J. Pelvic Floor Dysfunct. 24, 537–543.

Tomas, M.S.J., Macias, M.E.N., 2007. Effect of a medium simulating vaginal fluid on the growth and expression of beneficial characteristics of potentially probiotic lactobacilli. Commun. Curr. Res. Educ. Top. Trends Appl. Microbiol.

Valenta, C., Kast, C.E., Harich, I., Bernkop-Schnürch, A., 2001. Development and in vitro evaluation of a mucoadhesive vaginal delivery system for progesterone. J. Control. Release 77, 323–332.

van Schalkwyk, J., Yudin, M.H., Allen, V., Bouchard, C., Boucher, M., Boucoiran, I., Caddy, S., Castillo, E., Kennedy, V.L., Money, D.M., Murphy, K., Ogilvie, G., Paquet, C., 2015. Vulvovaginitis: Screening for and Management of Trichomoniasis, Vulvovaginal Candidiasis, and Bacterial Vaginosis. J. Obstet. Gynaecol. Canada 37, 266–274.

Vernekar, A., Gude, R., Ghadi, N., Parab, S., Shirodker, A., 2019. Formulation and characterization of controlled release flurbiprofen microsponges loaded in gels. Indian J. Pharm. Educ. Res. 53, s50–s57.

Wahid, A.A., 2016. Journal of Drug Delivery Research Microsponge : a Novel

Topical Review Article Microsponge : a System Novel Topical Drug.

Yadav, V., Jadhav, P., Dombe, S., Bodhe, A., Salunkhe, P., 2017. Formulation and evaluation of microsponge gel for topical delivery of antifungal drug. Int. J. Appl. Pharm. 9, 30–37.

Zhu, Z., Zhai, Y., Zhang, N., Leng, D., Ding, P., 2013. The development of polycarbophil as a bioadhesive material in pharmacy. Asian J. Pharm. Sci. 8, 218–227.

LAMPIRAN I

SKEMA KERJA



Lampiran 2. Panjang Gelombang Maksimum dan Kurva Baku

Lampiran 2.1. Panjang Gelombang Maksimum



Gambar 19. Panjang gelombang maksimum

Lampiran 2.2. Kurva Baku



Gambar 20. Kurva Baku Cairan vagina



Gambar 21. Kurva baku metanol

Lampiran 3. Perhitungan

a. Uji Permeasi Vagina

1 mL formula tiap pengujian mengandung 10 mg itrakonazol

Persamaan: y=0,0378x-0,0058

Dimana: y=serapan; x= konsentrasi

- Pada F1 Replikasi 1 jam 0,5 diperoleh serapan =0,131

Sehingga, untuk mendapatkan konsentrasi:

0,131 = 0,0378 x-0,0058

$$x = \frac{0,131+0,0058}{0,0378}$$

x = 3,61 µg/mL

Konsentrasi dalam 1,5 mL = 3,61x 1,5 = 5,41 µg/mL

$$\text{Konsentrasi dalam 28 mL} = \frac{= 3,61904762 \text{ x } 28 \text{ mL}}{1000} = 0,10 \text{ mg}$$

$$\text{Faktor koreksi} = \frac{\text{Konsentrasi jam sebelumnya}}{1000} + \text{Faktor koreksi jam sebelumnya}$$

$$= \frac{0 \text{ µg}}{1000} + 0$$

= 0

Jumlah terpermeasi = Konsentrasi dalam 28 mL + Faktor koreksi

= 0,10 mg + 0

= 0,10 mg

Kecepatan laju permease sediaan (fluks, J, µg/cm^{-2}/jam^{-1}) dihitung dengan rumus:

$$J = \frac{M}{S \times t}$$

Dimana :

J = Fluks (µg/cm^{-2}/jam^{-1})

S = Luas area difusi (cm^2)

M = Jumlah zat yang terpermeasi (µg)

t = Waktu (jam)

Maka,

$$J = \frac{0{,}0001\ \mu g}{4{,}9\ cm^2 \times 0{,}5\ jam} = 0{,}00004082\ \mu g/cm^{-2}/jam^{-1}$$

- Pada F1 Replikasi 1 jam 0,75 diperoleh serapan =0,239

Sehingga, untuk mendapatkan konsentrasi:

0,239 = 0,0378 x-0,0058

$$x = \frac{0{,}239+0{,}0058}{0{,}0378}$$

x = 6,46 µg/mL

Konsentrasi dalam 1,5 mL = 6,46 x 1,5 = 9,69 µg

$$\text{Konsentrasi dalam 28 mL} = \frac{= 6{,}46 \times 28\ mL}{1000} = 0{,}18\ mg$$

Faktor koreksi bernilai 0,01, diperoleh dari,

$$\text{Faktor koreksi} = \frac{\text{Konsentrasi jam sebelumnya}}{1000}$$

+ Faktor koreksi jam sebelumnya pada replikasi yang sama.

$$= \frac{5{,}41\ \mu g}{1000} + 0$$

= 0,01 mg

Jumlah terpermeasi = Konsentrasi dalam 28 mL + Faktor koreksi

= 0,18 mg + 0,01

= 0,19 mg

Kecepatan laju permeasi sediaan (fluks, J, µg/cm^{-2}/jam^{-1}) :

$$\boldsymbol{J} = \frac{0{,}00019\ \mu g}{4{,}9\ cm^2 \times 0{,}75\ jam} = 0{,}0000517\ \mu g/cm^{-2}/jam^{-1}$$

b. Uji Retensi Vagina

Persamaan: y= 0,0424 x - 0,0065

Dimana: y= serapan; x=konsentrasi

Pada F3 Replikasi 1, diperoleh serapan = 1,218

Sehingga, untuk mendapatkan konsentrasi:

1,218 = 0,0424x -0,0065

$$x = \frac{1{,}218+0{,}0065}{0{,}0424}$$

x = 28,88 µg/mL

Jumlah ITZ yang terdeposisi = $\frac{28{,}88}{1000}$ x 50 mL x 30 mL = 1,44 mg

Lampiran 4. Tabel Hasil Evaluasi

Lampiran 4.1 Hasil Uji pH

Replikasi	F1	F2	F3	F4
1	6,98	7,03	7,12	7,31
2	6,79	6,89	6,94	7,11
3	7,03	7,14	7,05	7,07
Rata-rata±SD	6,93 ± 0,13	7,02 ± 0,13	7,04 ± 0,09	7,16 ± 0,13

Lampiran 4.2 Hasil Uji Viskositas

Replikasi	F1	F2	F3	F4
1	26200	31400	35600	47600
2	24200	32700	38000	43700
3	25300	32100	38400	48800
Rata-rata ± SD	25233,33 ± 1001,67	32066,67 ± 650,64	37333,33 ± 1514,38	46700 ± 2666,46

Lampiran 4.3 Hail Uji Waktu Mukoadhesif

Replikasi	Waktu (jam)			
	F1	F2	F3	F4
1	2,5	3,9	6,3	6,7
2	2,1	4,2	6,2	6,3
3	2,3	4,1	6,4	6,4
Rata-rata ± SD	2,3 ± 0,20	4,07 ± 0,15	6,30 ± 0,10	6,47 ± 0,21

Lampiran 4.4 Hasil Uji Permeasi

(a) Formula Kontrol

Jam	Replikasi	Serapan	Konsentrasi (µg/ml)	1.5 ml (µg)	28 ml (mg)	Faktor koreksi	Jumlah Terpemeasi (mg)	Rata-rata ±SD
0,25	1	0,149	3,78	5,67	0,11	0,00	0,11	0,25 ± 0,12
	2	0,139	10,68	16,03	0,30	0,00	0,30	
	3	0,154	11,90	17,86	0,33	0,00	0,33	
0,5	1	0,272	21,27	31,90	0,60	0,01	0,60	0,66 ± 0,05
	2	0,313	24,53	36,79	0,69	0,02	0,70	
	3	0,303	23,71	35,57	0,66	0,02	0,68	
0,75	1	0,369	29,00	43,51	0,81	0,04	0,85	0,95 ± 0,11
	2	0,457	35,93	53,89	1,01	0,05	1,06	
	3	0,400	31,45	47,17	0,88	0,05	0,93	
1	1	0,508	40,00	60,00	1,12	0,08	1,20	1,25 ± 0,05
	2	0,523	41,22	61,83	1,15	0,11	1,26	
	3	0,544	42,85	64,27	1,20	0,10	1,30	
2	1	0,605	47,73	71,60	1,34	0,14	1,48	1,51 ± 0,03
	2	0,621	48,95	73,43	1,37	0,17	1,54	
	3	0,610	48,14	72,21	1,35	0,16	1,51	
3	1	0,826	65,22	97,83	1,83	0,21	2,04	2,05 ± 0,04
	2	0,838	66,16	99,24	1,85	0,24	2,09	
	3	0,808	63,80	95,71	1,79	0,24	2,02	
4	1	0,944	74,65	111,97	2,09	0,31	2,40	2,42 ± 0,03
	2	0,956	75,59	113,39	2,12	0,34	2,46	

	3	0,933	73,70	110,56	2,06	0,33	2,40	
	1	0,968	76,53	114,80	2,14	0,42	2,57	
5	2	1,004	79,36	119,04	2,22	0,45	2,68	2,63 ± 0,06
	3	0,998	78,89	118,34	2,21	0,44	2,65	
	1	1,016	80,30	120,46	2,25	0,54	2,79	
6	2	1,004	79,36	119,04	2,22	0,57	2,80	2,76 ± 0,08
	3	0,944	74,65	111,97	2,09	0,56	2,65	

(b) Formula 1 (F1)

Jam	Replikasi	Serapan	Konsentrasi (µg/ml)	1.5 ml (µg)	28 ml (mg)	Faktor koreksi	Jumlah Terpemeasi (mg)	Rata-Rata ± SD
	1	0,000	0,00	0,00	0,00	0,00	0,00	
0,25	2	0,000	0,00	0,00	0,00	0,00	0,00	0
	3	0,000	0,00	0,00	0,00	0,00	0,00	
	1	0,131	3,61	5,41	0,10	0,00	0,10	
0,5	2	0,122	3,37	5,05	0,09	0,00	0,09	0,10 ± 0,01
	3	0,135	3,72	5,59	0,10	0,00	0,10	
	1	0,239	6,46	9,69	0,18	0,01	0,19	
0,75	2	0,275	7,42	11,12	0,21	0,01	0,21	0,20 ± 0,01
	3	0,266	7,18	10,77	0,20	0,01	0,21	
	1	0,324	8,72	13,09	0,24	0,02	0,26	
1	2	0,401	10,75	16,12	0,30	0,02	0,32	0,29 ± 0,03
	3	0,351	9,44	14,16	0,26	0,02	0,28	
2	1	0,446	11,94	17,91	0,33	0,03	0,36	0,38 ± 0,01
	2	0,459	12,30	18,44	0,34	0,03	0,38	

	3	0,477	12,77	19,16	0,36	0,03	0,39	
	1	0,531	14,20	21,30	0,40	0,05	0,44	
3	2	0,545	14,56	21,84	0,41	0,05	0,46	0,45 ± 0,01
	3	0,536	14,32	21,48	0,40	0,05	0,45	
	1	0,626	16,70	25,05	0,47	0,07	0,54	
4	2	0,635	16,94	25,41	0,47	0,07	0,55	0,54 ± 0,01
	3	0,612	16,34	24,52	0,46	0,07	0,53	
	1	0,716	19,08	28,62	0,53	0,09	0,63	
5	2	0,725	19,32	28,98	0,54	0,10	0,64	0,63 ± 0,01
	3	0,707	18,84	28,27	0,53	0,10	0,62	
	1	0,734	19,56	29,34	0,55	0,12	0,67	
6	2	0,761	20,27	30,41	0,57	0,13	0,69	0,68 ± 0,01
	3	0,756	20,15	30,23	0,56	0,12	0,69	

(c) Formula 2 (F2)

Jam	Replikasi	Serapan	Konsentrasi (µg/ml)	1.5 ml (µg)	28 ml (mg)	Faktor koreksi	Jumlah Terpemeasi (mg)	Rata-Rata±SD
	1	0,000	0,00	0,00	0,00	0,00	0,00	
0,25	2	0,000	0,00	0,00	0,00	0,00	0,00	0
	3	0,000	0,00	0,00	0,00	0,00	0,00	
	1	0,000	0,00	0,00	0,00	0,00	0,00	
0,5	2	0,000	0,00	0,00	0,00	0,00	0,00	0
	3	0,000	0,00	0,00	0,00	0,00	0,00	
0,75	1	0,133	3,67	5,51	0,10	0,00	0,10	0,10 ± 0,01

	2	0,124	3,43	5,15	0,10	0,00	0,10	
	3	0,138	3,80	5,69	0,11	0,00	0,11	
	1	0,243	6,59	9,88	0,18	0,01	0,19	
1	2	0,280	7,56	11,34	0,21	0,01	0,22	0,21 ± 0,01
	3	0,271	7,32	10,98	0,20	0,01	0,21	
	1	0,330	8,90	13,34	0,25	0,02	0,26	
2	2	0,409	10,96	16,44	0,31	0,02	0,32	0,29 ± 0,03
	3	0,358	9,62	14,44	0,27	0,02	0,29	
	1	0,386	10,36	15,55	0,29	0,03	0,32	
3	2	0,398	10,67	16,01	0,30	0,03	0,33	0,33 ± 0,01
	3	0,413	11,09	16,63	0,31	0,03	0,34	
	1	0,460	12,32	18,49	0,35	0,04	0,39	
4	2	0,472	12,63	18,95	0,35	0,05	0,40	0,40 ± 0,01
	3	0,464	12,43	18,64	0,35	0,05	0,40	
	1	0,542	14,49	21,74	0,41	0,06	0,47	
5	2	0,550	14,70	22,05	0,41	0,07	0,48	0,47 ± 0,01
	3	0,530	14,18	21,27	0,40	0,07	0,46	
	1	0,620	16,55	24,83	0,46	0,08	0,55	
6	2	0,628	16,76	25,14	0,47	0,09	0,56	0,55 ± 0,01
	3	0,612	16,35	24,52	0,46	0,09	0,55	

(d) Formula 3 (F3)

Jam	Replikasi	Serapan	Konsentrasi (µg/ml)	1.5 ml (µg)	28 ml (mg)	Faktor koreksi	Jumlah Terpemeasi (mg)	Rata-Rata ±SD
	1	0,000	0,00	0,00	0,00	0,00	0,00	
0,25	2	0,000	0,00	0,00	0,00	0,00	0,00	0
	3	0,000	0,00	0,00	0,00	0,00	0,00	
	1	0,000	0,00	0,00	0,00	0,00	0,00	
0,5	2	0,000	0,00	0,00	0,00	0,00	0,00	0
	3	0,000	0,00	0,00	0,00	0,00	0,00	
	1	0,000	0,00	0,00	0,00	0,00	0,00	
0,75	2	0,000	0,00	0,00	0,00	0,00	0,00	0
	3	0,000	0,00	0,00	0,00	0,00	0,00	
	1	0,000	0,00	0,00	0,00	0,00	0,00	
1	2	0,000	0,00	0,00	0,00	0,00	0,00	0
	3	0,000	0,00	0,00	0,00	0,00	0,00	
	1	0,159	4,35	6,53	0,12	0,00	0,12	
2	2	0,196	5,34	8,01	0,15	0,00	0,15	0,13 ± 0,01
	3	0,172	4,70	7,05	0,13	0,00	0,13	
	1	0,185	5,05	7,58	0,14	0,01	0,15	
3	2	0,191	5,20	7,81	0,15	0,01	0,15	0,15 ± 0,01
	3	0,198	5,40	8,10	0,15	0,01	0,16	
	1	0,216	5,88	8,82	0,16	0,01	0,18	
4	2	0,222	6,02	9,04	0,17	0,02	0,18	0,18 ± 0,00
	3	0,218	5,93	8,89	0,17	0,02	0,18	

	1	0,238	6,46	9,69	0,18	0,02	0,20	
5	2	0,274	7,41	11,12	0,21	0,02	0,23	0,22 ± 0,01
	3	0,265	7,17	10,76	0,20	0,02	0,22	
	1	0,324	8,72	13,08	0,24	0,03	0,28	
6	2	0,400	10,74	16,12	0,30	0,04	0,34	0,30 ± 0,03
	3	0,351	9,44	14,15	0,26	0,03	0,30	

(e) Formula 4 (F4)

Jam	Replikasi	Serapan	Konsentrasi (µg/ml)	1.5 ml (µg)	28 ml (mg)	Faktor koreksi	Jumlah Terpemeasi (mg)	Rata-rata±SD
	1	0,000	0,00	0,00	0,00	0,00	0,00	
0,25	2	0,000	0,00	0,00	0,00	0,00	0,00	0
	3	0,000	0,00	0,00	0,00	0,00	0,00	
	1	0,000	0,00	0,00	0,00	0,00	0,00	
0,5	2	0,000	0,00	0,00	0,00	0,00	0,00	0
	3	0,000	0,00	0,00	0,00	0,00	0,00	
	1	0,000	0,00	0,00	0,00	0,00	0,00	
0,75	2	0,000	0,00	0,00	0,00	0,00	0,00	0
	3	0,000	0,00	0,00	0,00	0,00	0,00	
	1	0,000	0,00	0,00	0,00	0,00	0,00	
1	2	0,000	0,00	0,00	0,00	0,00	0,00	0
	3	0,000	0,00	0,00	0,00	0,00	0,00	
2	1	0,000	0,00	0,00	0,00	0,00	0,00	0

	2	0,000	0,00	0,00	0,00	0,00	0,00	
	3	0,000	0,00	0,00	0,00	0,00	0,00	
	1	0,000	0,00	0,00	0,00	0,00	0,00	
3	2	0,000	0,00	0,00	0,00	0,00	0,00	0
	3	0,000	0,00	0,00	0,00	0,00	0,00	
	1	0,119	3,30	4,95	0,09	0,00	0,09	
4	2	0,147	4,04	6,07	0,11	0,00	0,11	0,10 ± 0,01
	3	0,129	3,56	5,34	0,10	0,00	0,10	
	1	0,139	3,83	5,74	0,11	0,00	0,11	
5	2	0,143	3,94	5,91	0,11	0,01	0,12	0,12 ± 0,00
	3	0,149	4,09	6,13	0,11	0,01	0,12	
	1	0,158	4,33	6,50	0,12	0,01	0,13	
6	2	0,162	4,44	6,66	0,12	0,01	0,14	0,13 ± 0,00
	3	0,159	4,37	6,55	0,12	0,01	0,13	

Lampiran 4.5 Hasil Uji Retensi

Formula	Replikasi	Serapan	Konsentrasi (µg/ml)	Jumlah ITZ terdeposisi setelah 6 jam (mg)	Rata-rat ±SD
KONTROL	1	0,050	1,32	0,07	0,06 ± 0,00
	2	0,042	1,14	0,05	
	3	0,048	1,28	0,06	
F1	1	0,297	7,16	0,35	0,38 ± 0,02
	2	0,327	7,87	0,40	
	3	0,314	7,54	0,37	
F2	1	0,471	11,26	0,56	0,54 ± 0,03
	2	0,431	10,30	0,40	
	3	0,464	11,08	0,56	
F3	1	1,218	28,88	1,44	1,45 ± 0,03
	2	1,248	29,60	1,48	
	3	1,197	28,38	1,42	
F4	1	0,041	1,10	0,06	0,06 ± 0,00
	2	0,047	1,25	0,06	
	3	0,039	1,07	0,06	

Lampiran 5. Data Hasil Analisis Statistika

(a) pH

Oneway

ANOVA

pH

	Sum of Squares	Df	Mean Square	F	Sig.
Between Groups	.081	3	.027	1.911	.206
Within Groups	.113	8	.014		
Total	.194	11			

(b) Viskositas

Oneway

ANOVA

Viskositas

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	737646666.667	3	245882222.222	90.815	.000
Within Groups	21660000.000	8	2707500.000		
Total	759306666.667	11			

Post Hoc Tests

Multiple Comparisons

Dependent Variable: Viskositas

Tukey HSD

(I) Formula	(J) Formula	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
Formula 1	Formula 2	-6833.33333*	1343.50288	.004	-11135.7025	-2530.9642
	Formula 3	-12100.00000*	1343.50288	.000	-16402.3692	-7797.6308
	Formula 4	-21466.66667*	1343.50288	.000	-25769.0358	-17164.2975
Formula 2	Formula 1	6833.33333*	1343.50288	.004	2530.9642	11135.7025

	Formula 3	-5266.66667*	1343.50288	.019	-9569.0358	-964.2975
	Formula 4	-14633.33333*	1343.50288	.000	-18935.7025	-10330.9642
Formula 3	Formula 1	12100.00000*	1343.50288	.000	7797.6308	16402.3692
	Formula 2	5266.66667*	1343.50288	.019	964.2975	9569.0358
	Formula 4	-9366.66667*	1343.50288	.001	-13669.0358	-5064.2975
Formula 4	Formula 1	21466.66667*	1343.50288	.000	17164.2975	25769.0358
	Formula 2	14633.33333*	1343.50288	.000	10330.9642	18935.7025
	Formula 3	9366.66667*	1343.50288	.001	5064.2975	13669.0358

(c) Waktu Mukhoadhesif

Kruskal-Wallis Test

Ranks

	Formula	N	Mean Rank
Waktu Mukoadhesif	Formula 1	3	2.00
	Formula 2	3	5.00
	Formula 3	3	8.67
	Formula 4	3	10.33
	Total	12	

Test Statistics[a,b]

	Waktu Mukoadhesif
Chi-Square	9.735
Df	3
Asymp. Sig.	.021

Post Hoc Tests

Multiple Comparisons

Dependent Variable: WaktuMukoadhesif

Tukey HSD

(I) Formula	(J) Formula		Std. Error	Sig.	95% Confidence Interval

		Mean Difference (I-J)			Lower Bound	Upper Bound
Formula 1	Formula 2	-1.7667*	.1394	.000	-2.213	-1.320
	Formula 3	-4.0000*	.1394	.000	-4.447	-3.553
	Formula 4	-4.1667*	.1394	.000	-4.613	-3.720
Formula 2	Formula 1	1.7667*	.1394	.000	1.320	2.213
	Formula 3	-2.2333*	.1394	.000	-2.680	-1.787
	Formula 4	-2.4000*	.1394	.000	-2.847	-1.953
Formula 3	Formula 1	4.0000*	.1394	.000	3.553	4.447
	Formula 2	2.2333*	.1394	.000	1.787	2.680
	Formula 4	-.1667	.1394	.646	-.613	.280
Formula 4	Formula 1	4.1667*	.1394	.000	3.720	4.613
	Formula 2	2.4000*	.1394	.000	1.953	2.847
	Formula 3	.1667	.1394	.646	-.280	.613

*. The mean difference is significant at the 0.05 level.

(d) Permeasi

Kruskal-Wallis Test

Ranks

	Formula	N	Mean Rank
Permeasi	Kontrol	3	14.00
	Formula 1	3	11.00
	Formula 2	3	8.00
	Formula 3	3	5.00
	Formula 4	3	2.00
	Total	15	

Test Statistics[a,b]

	Permeasi
Chi-Square	13.573
Df	4

Asymp. Sig.	.009

a. Kruskal Wallis Test

b. Grouping Variable:

Formula

Post Hoc Tests

Multiple Comparisons

Dependent Variable: Permeasi

Tukey HSD

(I) Formula	(J) Formula	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
Kontrol	Formula 1	2.06333*	.03300	.000	1.9547	2.1719
	Formula 2	2.19333*	.03300	.000	2.0847	2.3019
	Formula 3	2.44000*	.03300	.000	2.3314	2.5486
	Formula 4	2.61333*	.03300	.000	2.5047	2.7219
Formula 1	Kontrol	-2.06333*	.03300	.000	-2.1719	-1.9547
	Formula 2	.13000*	.03300	.018	.0214	.2386
	Formula 3	.37667*	.03300	.000	.2681	.4853
	Formula 4	.55000*	.03300	.000	.4414	.6586
Formula 2	Kontrol	-2.19333*	.03300	.000	-2.3019	-2.0847
	Formula 1	-.13000*	.03300	.018	-.2386	-.0214
	Formula 3	.24667*	.03300	.000	.1381	.3553
	Formula 4	.42000*	.03300	.000	.3114	.5286
Formula 3	Kontrol	-2.44000*	.03300	.000	-2.5486	-2.3314
	Formula 1	-.37667*	.03300	.000	-.4853	-.2681
	Formula 2	-.24667*	.03300	.000	-.3553	-.1381
	Formula 4	.17333*	.03300	.003	.0647	.2819
Formula 4	Kontrol	-2.61333*	.03300	.000	-2.7219	-2.5047
	Formula 1	-.55000*	.03300	.000	-.6586	-.4414
	Formula 2	-.42000*	.03300	.000	-.5286	-.3114
	Formula 3	-.17333*	.03300	.003	-.2819	-.0647

(e)

*. The mean difference is significant at the 0.05 level.

(f) Retensi

Ranks

	Formula	N	Mean Rank
Retensi	Kontrol	3	4.33
	Formula 1	3	8.00
	Formula 2	3	11.00
	Formula 3	3	14.00
	Formula 4	3	2.67
	Total	15	

Test Statistics[a,b]

	Retensi
Chi-Square	13.270
df	4
Asymp. Sig.	.010

a. Kruskal Wallis Test

b. Grouping Variable: Formula

Post Hoc Tests

Multiple Comparisons

Dependent Variable: Retensi

Tukey HSD

(I) Formula	(J) Formula	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
Kontrol	Formula 1	-.31333*	.01491	.000	-.3624	-.2643
	Formula 2	-.48000*	.01491	.000	-.5291	-.4309
	Formula 3	-1.38333*	.01491	.000	-1.4324	-1.3343
	Formula 4	.00667	.01491	.990	-.0424	.0557
Formula 1	Kontrol	.31333*	.01491	.000	.2643	.3624

	Formula 2	-.16667*	.01491	.000	-.2157	-.1176
	Formula 3	-1.07000*	.01491	.000	-1.1191	-1.0209
	Formula 4	.32000*	.01491	.000	.2709	.3691
Formula 2	Kontrol	.48000*	.01491	.000	.4309	.5291
	Formula 1	.16667*	.01491	.000	.1176	.2157
	Formula 3	-.90333*	.01491	.000	-.9524	-.8543
	Formula 4	.48667*	.01491	.000	.4376	.5357
Formula 3	Kontrol	1.38333*	.01491	.000	1.3343	1.4324
	Formula 1	1.07000*	.01491	.000	1.0209	1.1191
	Formula 2	.90333*	.01491	.000	.8543	.9524
	Formula 4	1.39000*	.01491	.000	1.3409	1.4391
Formula 4	Kontrol	-.00667	.01491	.990	-.0557	.0424
	Formula 1	-.32000*	.01491	.000	-.3691	-.2709
	Formula 2	-.48667*	.01491	.000	-.5357	-.4376
	Formula 3	-1.39000*	.01491	.000	-1.4391	-1.3409

*. The mean difference is significant at the 0.05 level.

Lampiran 6. Gambar Penelitian



Gambar 22. (a) Sediaan basis gel tanpa *microsponge* ITZ (b) Penampakan morfologi *microsponge* ITZ



Gambar 23. Tahapan uji mukoadhesif gel (a) penjepitan pada *paddle,* (b) pemasangan *paddle* pada alat disolusi, (c) proses uji mukoadhesif dengan rotating *cylinder method*



Gambar 24. (a) evaluasi pH, (b) evaluasi viskositas, (c) aparatus sel difusi Franz